| Literature DB >> 29091756 |
Lorène J Lebrun1, Kaatje Lenaerts2, Dorien Kiers3, Jean-Paul Pais de Barros1, Naig Le Guern1, Jiri Plesnik1, Charles Thomas1, Thibaut Bourgeois1, Cornelis H C Dejong4, Matthijs Kox3, Inca H R Hundscheid2, Naim Akhtar Khan1, Stéphane Mandard1, Valérie Deckert1, Peter Pickkers3, Daniel J Drucker5, Laurent Lagrost6, Jacques Grober7.
Abstract
Glucagon-like peptide 1 (GLP-1) is a hormone released from enteroendocrine L cells. Although first described as a glucoregulatory incretin hormone, GLP-1 also suppresses inflammation and promotes mucosal integrity. Here, we demonstrate that plasma GLP-1 levels are rapidly increased by lipopolysaccharide (LPS) administration in mice via a Toll-like receptor 4 (TLR4)-dependent mechanism. Experimental manipulation of gut barrier integrity after dextran sodium sulfate treatment, or via ischemia/reperfusion experiments in mice, triggered a rapid rise in circulating GLP-1. This phenomenon was detected prior to measurable changes in inflammatory status and plasma cytokine and LPS levels. In human subjects, LPS administration also induced GLP-1 secretion. Furthermore, GLP-1 levels were rapidly increased following the induction of ischemia in the human intestine. These findings expand traditional concepts of enteroendocrine L cell biology to encompass the sensing of inflammatory stimuli and compromised mucosal integrity, linking glucagon-like peptide secretion to gut inflammation.Entities:
Keywords: TLR4; enteroendocrine cells; glucagon-like peptide 1; gut injury; inflammation; intestinal ischemia; lipopolysaccharides
Mesh:
Substances:
Year: 2017 PMID: 29091756 DOI: 10.1016/j.celrep.2017.10.008
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423